Shares of CELLECT BIOTECH / S (NASDAQ: APOP) received an average brokerage score of 1.00 (Strong Buy) from the only brokers offering coverage for the shares, reports Zacks Investment Research. A research analyst for shares has assessed the shares with a recommendation for a strong buy.
Brokers set a 12-month consensus target at $ 14.00 for the company and predicted that the company ($ 0.28) will post earnings per share for the current quarter, Zacks said. Zacks also gave CELLECT BIOTECH / S an industry rank of 90 out of 255 based on the ratings given to related companies.
Several brokers have weighed on APOP. Zacks Investment Research reduced shares of CELLECT BIOTECH / S from a "buy" rating to a "hold" rating in a research note on Tuesday, July 31. HC Wainwright set a target price of $ 14.00 on CELLECT BIOTECH / S shares and gave the shares a "buy" rating in a study letter on Friday, July 6. Finally, ValuEngine increased CELLECT BIOTECH / S shares from a "sell" classification to a "hold" rating in a study letter on Wednesday, June 6.
An institutional investor recently acquired a new position in CELLECT BIOTECH / S shares. Sabby Management LLC acquired a new stake in CELLECT BIOTECH / S (NASDAQ: APOP) in the first quarter, according to the company in its most recent Form 13F application with the Securities and Exchange Commission (SEC). The company acquired 243,980 shares of the company's stock, valued at approximately $ 1,557,000. CELLECT BIOTECH / S accounts for approximately 0.2% of the investment portfolio of Sabby Management LLC, making the equity bank the 23rd largest shareholder. Sabby Management LLC owned 4.48% of CELLECT BIOTECH / S at the end of the most recent reporting period. 6.19% of the shares are currently held by institutional investors.
APOP shares traded $ 0.03 during mid-day trading on Monday and reached $ 4.79. 2,025 shares of the company were traded, compared with the average volume of 36,326. The company has a market capitalization of $ 25.95 million, a PE ratio of -3.28 and a beta of 3.99. CELLECT BIOTECH / S has a 12 month low of $ 4.40 and a 12 month high of $ 13.50.
CELLECT BIOTECH / S (NASDAQ: APOP) last announced its earnings on Thursday 9 August. The company reported ($ 0.26) earnings per share for the quarter, on top of the Thomson Reuters & # 39; consensus estimate of ($ 0.29) with $ 0.03. sell-side analysts expect that CELLECT will publish BIOTECH / S -1 EPS for the current fiscal year.
CELLECT BIOTECH / S Company profile
Cellect Biotechnology Ltd., a biotechnology company, focuses on the development of technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It develops the Apotainer selection kit, a plank stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic haematopoietic stem cell transplantation procedures for patients suffering from haematological malignancies.
Featured article: Google Finance Portfolio
Receive a free copy of the Zack research report on CELLECT BIOTECH / S (APOP)
Visit Zacks.com for more information about research offers from Zacks Investment Research
Receive news and ratings for CELLECT BIOTECH / S Daily – Enter your email address below for a concise, daily summary of the latest news and ratings from analysts for CELLECT BIOTECH / S and related companies with the FREE daily email newsletter from MarketBeat.com.